The effects of Lactobacilli from raw meat beef on E. coli O157: H7

Background and aims: Lactobacilli are widely distributed in the nature and are present almost everywhere. Because the bacteria are present in various food products, they are used for many years in foods. Studies show lactobacilli has antibacterial properties. The aim of this study was to isolate and identify the species of Lactobacillus from raw beef meat samples and evaluate their antibacterial properties. Methods: In this experimental study, 72 samples of raw beef meat were obtained from slaughterhouses of Sanandaj city. Isolates were evaluated using phenotypic methods (morphology, gram stain and catalase test). In order to identify more precisely, the fermentation of sugars test and molecular polymerase chain reaction (PCR) methods were used. Then, agar well diffusion and spot on plate methods were used to evaluate antibacterial properties of lactobacilli against E. coli O157: H7. Results: A total of 8 species Lactobacilli were isolated from raw beef meat and identified by chemical and molecular methods. The results showed that these 8 species of lactobacilli inhibited E. coli O157: H7 well. These results statistically was considered significant (P<0.05). Conclusion: The results of this study show that raw beef meat has different lactobacilli that can be used as a biological control in foods

Evaluation of the Relationship of Low Back Pain with Spinal Anesthesia and its Related Factors in Patients Undergoing Urological Surgery

Background: Spinal anesthesia is the common method in outpatient surgeries, which has complications such as back pain. We aimed to evaluate the relationship between low back pain (LBP) with spinal anesthesia and its related factors in patients undergoing urological surgery. Materials and methods: In this cross-sectional study, 1000 patients undergoing urological surgery were enrolled. The severity of LBP was measured using the VAS (visual analog scale) pain on the 1st day, the 1st week, and the 1st month postoperatively. Patients’ age, sex, and the duration of surgery were collected. data analysis was performed using SPSS software, version 17. Results: Of the 1000 patients undergoing urological surgery, 636 (63.6%) patients and 364 (36.5%) patients underwent spinal and general anesthesia, respectively. In patients under general anesthesia, the LBP prevalence was higher than in patients under spinal anesthesia on the 1st week and the 1st month after surgery (P&lt;0.05). So, the LBP prevalence was as follows: on the 1st day (general anesthesia: 14.5% vs spinal anesthesia: 24.1%, p=0.09), at the 1st week (general anesthesia: 24.9% vs spinal anesthesia:13.5%, P=0.001) and the1th month (general anesthesia: 13.8% vs spinal anesthesia: 4%, P=0.001). On 1st day and 1st week after surgery, the rate of LBP was significantly higher in the &gt;45-year age group than in the age group less than 45 years (P&lt;0.05). The pain rate was higher in patients who had surgery duration of more than 2.5 hours in all three time periods (P=0.001). Conclusion: Although the LBP prevalence on 1st day after surgery in patients undergoing urological surgeries under spinal anesthesia was higher than in patients who underwent general anesthesia, there was a significant decrease in pain levels during the first week and month following the surgery in patients under spinal anesthesia. Older age and longer duration of surgery were related factors to pain

Adolescent transport and unintentional injuries: a systematic analysis using the Global Burden of Disease Study 2019

Background: Globally, transport and unintentional injuries persist as leading preventable causes of mortality and morbidity for adolescents. We sought to report comprehensive trends in injury-related mortality and morbidity for adolescents aged 10–24 years during the past three decades. Methods: Using the Global Burden of Disease, Injuries, and Risk Factors 2019 Study, we analysed mortality and disability-adjusted life-years (DALYs) attributed to transport and unintentional injuries for adolescents in 204 countries. Burden is reported in absolute numbers and age-standardised rates per 100 000 population by sex, age group (10–14, 15–19, and 20–24 years), and sociodemographic index (SDI) with 95% uncertainty intervals (UIs). We report percentage changes in deaths and DALYs between 1990 and 2019. Findings: In 2019, 369 061 deaths (of which 214 337 [58%] were transport related) and 31·1 million DALYs (of which 16·2 million [52%] were transport related) among adolescents aged 10–24 years were caused by transport and unintentional injuries combined. If compared with other causes, transport and unintentional injuries combined accounted for 25% of deaths and 14% of DALYs in 2019, and showed little improvement from 1990 when such injuries accounted for 26% of adolescent deaths and 17% of adolescent DALYs. Throughout adolescence, transport and unintentional injury fatality rates increased by age group. The unintentional injury burden was higher among males than females for all injury types, except for injuries related to fire, heat, and hot substances, or to adverse effects of medical treatment. From 1990 to 2019, global mortality rates declined by 34·4% (from 17·5 to 11·5 per 100 000) for transport injuries, and by 47·7% (from 15·9 to 8·3 per 100 000) for unintentional injuries. However, in low-SDI nations the absolute number of deaths increased (by 80·5% to 42 774 for transport injuries and by 39·4% to 31 961 for unintentional injuries). In the high-SDI quintile in 2010–19, the rate per 100 000 of transport injury DALYs was reduced by 16·7%, from 838 in 2010 to 699 in 2019. This was a substantially slower pace of reduction compared with the 48·5% reduction between 1990 and 2010, from 1626 per 100 000 in 1990 to 838 per 100 000 in 2010. Between 2010 and 2019, the rate of unintentional injury DALYs per 100 000 also remained largely unchanged in high-SDI countries (555 in 2010 vs 554 in 2019; 0·2% reduction). The number and rate of adolescent deaths and DALYs owing to environmental heat and cold exposure increased for the high-SDI quintile during 2010–19. Interpretation: As other causes of mortality are addressed, inadequate progress in reducing transport and unintentional injury mortality as a proportion of adolescent deaths becomes apparent. The relative shift in the burden of injury from high-SDI countries to low and low–middle-SDI countries necessitates focused action, including global donor, government, and industry investment in injury prevention. The persisting burden of DALYs related to transport and unintentional injuries indicates a need to prioritise innovative measures for the primary prevention of adolescent injury. Funding: Bill &amp; Melinda Gates Foundation

Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BackgroundDisorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19. Previous publications from the Global Burden of Disease, Injuries, and Risk Factor Study estimated the burden of 15 neurological conditions in 2015 and 2016, but these analyses did not include neurodevelopmental disorders, as defined by the International Classification of Diseases (ICD)-11, or a subset of cases of congenital, neonatal, and infectious conditions that cause neurological damage. Here, we estimate nervous system health loss caused by 37 unique conditions and their associated risk factors globally, regionally, and nationally from 1990 to 2021.MethodsWe estimated mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs), with corresponding 95% uncertainty intervals (UIs), by age and sex in 204 countries and territories, from 1990 to 2021. We included morbidity and deaths due to neurological conditions, for which health loss is directly due to damage to the CNS or peripheral nervous system. We also isolated neurological health loss from conditions for which nervous system morbidity is a consequence, but not the primary feature, including a subset of congenital conditions (ie, chromosomal anomalies and congenital birth defects), neonatal conditions (ie, jaundice, preterm birth, and sepsis), infectious diseases (ie, COVID-19, cystic echinococcosis, malaria, syphilis, and Zika virus disease), and diabetic neuropathy. By conducting a sequela-level analysis of the health outcomes for these conditions, only cases where nervous system damage occurred were included, and YLDs were recalculated to isolate the non-fatal burden directly attributable to nervous system health loss. A comorbidity correction was used to calculate total prevalence of all conditions that affect the nervous system combined.FindingsGlobally, the 37 conditions affecting the nervous system were collectively ranked as the leading group cause of DALYs in 2021 (443 million, 95% UI 378–521), affecting 3·40 billion (3·20–3·62) individuals (43·1%, 40·5–45·9 of the global population); global DALY counts attributed to these conditions increased by 18·2% (8·7–26·7) between 1990 and 2021. Age-standardised rates of deaths per 100 000 people attributed to these conditions decreased from 1990 to 2021 by 33·6% (27·6–38·8), and age-standardised rates of DALYs attributed to these conditions decreased by 27·0% (21·5–32·4). Age-standardised prevalence was almost stable, with a change of 1·5% (0·7–2·4). The ten conditions with the highest age-standardised DALYs in 2021 were stroke, neonatal encephalopathy, migraine, Alzheimer's disease and other dementias, diabetic neuropathy, meningitis, epilepsy, neurological complications due to preterm birth, autism spectrum disorder, and nervous system cancer.InterpretationAs the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed

Global, regional, and national mortality among young people aged 10-24 years, 1950-2019: a systematic analysis for the Global Burden of Disease Study 2019

Background Documentation of patterns and long-term trends in mortality in young people, which reflect huge changes in demographic and social determinants of adolescent health, enables identification of global investment priorities for this age group. We aimed to analyse data on the number of deaths, years of life lost, and mortality rates by sex and age group in people aged 10-24 years in 204 countries and territories from 1950 to 2019 by use of estimates from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019. Methods We report trends in estimated total numbers of deaths and mortality rate per 100 000 population in young people aged 10-24 years by age group (10-14 years, 15-19 years, and 20-24 years) and sex in 204 countries and territories between 1950 and 2019 for all causes, and between 1980 and 2019 by cause of death. We analyse variation in outcomes by region, age group, and sex, and compare annual rate of change in mortality in young people aged 10-24 years with that in children aged 0-9 years from 1990 to 2019. We then analyse the association between mortality in people aged 10-24 years and socioeconomic development using the GBD Socio-demographic Index (SDI), a composite measure based on average national educational attainment in people older than 15 years, total fertility rate in people younger than 25 years, and income per capita. We assess the association between SDI and all-cause mortality in 2019, and analyse the ratio of observed to expected mortality by SDI using the most recent available data release (2017). Findings In 2019 there were 1.49 million deaths (95% uncertainty interval 1.39-1.59) worldwide in people aged 10-24 years, of which 61% occurred in males. 32.7% of all adolescent deaths were due to transport injuries, unintentional injuries, or interpersonal violence and conflict; 32.1% were due to communicable, nutritional, or maternal causes; 27.0% were due to non-communicable diseases; and 8.2% were due to self-harm. Since 1950, deaths in this age group decreased by 30.0% in females and 15.3% in males, and sex-based differences in mortality rate have widened in most regions of the world. Geographical variation has also increased, particularly in people aged 10-14 years. Since 1980, communicable and maternal causes of death have decreased sharply as a proportion of total deaths in most GBD super-regions, but remain some of the most common causes in sub-Saharan Africa and south Asia, where more than half of all adolescent deaths occur. Annual percentage decrease in all-cause mortality rate since 1990 in adolescents aged 15-19 years was 1.3% in males and 1.6% in females, almost half that of males aged 1-4 years (2.4%), and around a third less than in females aged 1-4 years (2.5%). The proportion of global deaths in people aged 0-24 years that occurred in people aged 10-24 years more than doubled between 1950 and 2019, from 9.5% to 21.6%. Interpretation Variation in adolescent mortality between countries and by sex is widening, driven by poor progress in reducing deaths in males and older adolescents. Improving global adolescent mortality will require action to address the specific vulnerabilities of this age group, which are being overlooked. Furthermore, indirect effects of the COVID-19 pandemic are likely to jeopardise efforts to improve health outcomes including mortality in young people aged 10-24 years. There is an urgent need to respond to the changing global burden of adolescent mortality, address inequities where they occur, and improve the availability and quality of primary mortality data in this age group. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd

Antibacterial effects of Artemisa aucheri leaf and Spirulina Blue-Green algae aqueous and alcoholic extracts on the multidrug-resistant Klebsiella pneumoniae isolated from the patients with pneumonia

ABSRTRACT Background and Aim: Antibacterial effects of Artemisia plant and algae have been confirmed. The purpose of this study was to evaluate the antibacterial effect of antibiotics, Spirulina blue-green algae and Artemisa aucheri leaf extracts on multidrug resistant (MDR) Klebsiella pneumoniae. Materials and Methods: Disk and well diffusion method, the growth minimum inhibitory and bactericidal concentrations (MIC and MBC) were used to evaluate antibacterial effects. Using SPPS 16 soaftware, data were analyzed by analysis of variance (ANOVA) with repeated measures and Bonferroni test (p≤0.001). Results: The MIC and MBC for amikacin, colicitin, ceftazidime were 4 and for gentamicin and nalidixic acid were 2 and 1 µg/µl, respectively. In disk and well diffusion methods, the highest growth inhibition zones belonged to ethanolic extracts (0.25 mg/ml) of Artemisia and algae. The best MIC and MBC for growth were related to ethanolic extracts of A. aucheri at the concentration of 0.15 mg/ml. The diameter of growth inhibition zone around the bacterium was directly related to the concentrations of Artemisia and Algae extracts (p = 0.000). Conclusion: Considering the beneficial antibacterial effects of Spirulina blue-green algae and A. aucheri which were confirmed in this study, extraction of the active ingredients of medicinal plants is recommended for the mass production of herbal medicines. Keywords: Antibacterial effect, Extracts, Artemisa aucheri, Spirulina blue-green algae, Klebsiella pneumonia

Effect of Probiotics on COVID-19 Infection: A Systematic Review

Background and Aim: Scientific evidence has shown that SARS-CoV-2 can infect intestinal epithelial cells and probiotics are capable of inducing immune responses against respiratory viruses. Since there have been no specific guidelines or treatment for the patients with COVID-19, we performed this systematic review of studies to investigate the effect of probiotics on COVID-19 infection. Materials and Methods: This study included relevant English original articles in the international databases of PubMed and Scopus using the keywords of "severe acute respiratory syndrome", "coronavirus 2", "sars-cov-2", "2019 novel coronavirus", "2019 nCoV", "new coronavirus, COVID-19", "probiotics" and the "combination of these keywords" between the beginning of 2018 and 20 July 2022. Results: A total of 424 articles were found among which 6 articles met the inclusion criteria for this study. The findings of this study showed that fever, cough, shortness of breath and diarrhea were the main symptoms of the patients with COVID-19. Also, consumption of probiotics using bacterial formula (Streptococcus thermophilus, Lactobacillus acidophilus, and Bifidobacterium spp) can be an effective treatment option to reduce the incidence of secondary infections and modulate immunity in the patients with SARS-CoV-2 infection. Conclusion: It seems that administration of probiotics in order to modulate the intestinal-lung immune axis as an adjunctive treatment can be useful for prevention and management of COVID-19 infection

Antibacterial effects of Artemisa aucheri leaf and Spirulina Blue-Green algae aqueous and alcoholic extracts on the multidrug-resistant Klebsiella pneumoniae isolated from the patients with pneumonia

Background and Aim: Antibacterial effects of Artemisia plant and algae have been confirmed. The purpose of this study was to evaluate the antibacterial effect of antibiotics, Spirulina blue-green algae and Artemisa aucheri leaf extracts on multidrug resistant (MDR) Klebsiella pneumoniae. Materials and Methods: Disk and well diffusion method, the growth minimum inhibitory and bactericidal concentrations (MIC and MBC) were used to evaluate antibacterial effects. Using SPPS 16 soaftware, data were analyzed by analysis of variance (ANOVA) with repeated measures and Bonferroni test (p≤0.001). Results: The MIC and MBC for amikacin, colicitin, ceftazidime were 4 and for gentamicin and nalidixic acid were 2 and 1 μg/μl, respectively. In disk and well diffusion methods, the highest growth inhibition zones belonged to ethanolic extracts (0.25 mg/ml) of Artemisia and algae. The best MIC and MBC for growth were related to ethanolic extracts of A. aucheri at the concentration of 0.15 mg/ml. The diameter of growth inhibition zone around the bacterium was directly related to the concentrations of Artemisia and Algae extracts (p = 0.000). Conclusion: Considering the beneficial antibacterial effects of Spirulina blue-green algae and A. aucheri which were confirmed in this study, extraction of the active ingredients of medicinal plants is recommended for the mass production of herbal medicines

The association between nutrients and occurrence of COVID‐19 outcomes in the population of Western Iran: A cohort study

Abstract Introduction The study aimed to determine the association between nutrients (micronutrients, macronutrients, and antioxidants) and the occurrence of COVID‐19‐related outcomes (morbidity and hospitalization) using a cohort study in Western Iran. Methods The basic study information was collected from February 2019 to February 2020 from the baseline phase of the Dehgolan Prospective Cohort Study (DehPCS). The primary outcomes in this study included risk of contracting COVID‐19 and hospitalization due to it at a specific time. To compare these outcomes based on different nutritional groups (macronutrients or micronutrients), Kaplan–Meier chart and log rank test were used. Also, univariate and multivariate regression models were used to investigate the association between different nutritional groups and desired outcomes (risk of contracting COVID‐19 and hospitalization due to it at a certain time). Results The results showed that people having an insufficient intake of selenium (HR: 1.180; % 95 CI: 1.032–2.490; P: 0.042), vitamin A (HR: 1.119; % 95 CI: 1.020–1.442; p: 0.033), and vitamin E (HR: 1.544; % 95 CI: 1.136–3.093; p: 0.039) were significantly more infected with COVID‐19 than the ones who had a sufficient intake of these nutrients. Also, the results showed that people having an insufficient intake of selenium (HR: 2.130; % 95 CI: 1.232–3.098; p: 0.018) and vitamin A (HR: 1.200; % 95 CI: 1.000–2.090; p: 0.043) were significantly hospitalized more than the ones who had a sufficient intake of these nutrients. Conclusion Insufficient intake of selenium and vitamins A and E can significantly increase the incidence of COVID‐19 and hospitalization due to it

Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990–2021: findings from the Global Burden of Disease Study 2021

Background: Anaemia is a major health problem worldwide. Global estimates of anaemia burden are crucial for developing appropriate interventions to meet current international targets for disease mitigation. We describe the prevalence, years lived with disability, and trends of anaemia and its underlying causes in 204 countries and territories. Methods: We estimated population-level distributions of haemoglobin concentration by age and sex for each location from 1990 to 2021. We then calculated anaemia burden by severity and associated years lived with disability (YLDs). With data on prevalence of the causes of anaemia and associated cause-specific shifts in haemoglobin concentrations, we modelled the proportion of anaemia attributed to 37 underlying causes for all locations, years, and demographics in the Global Burden of Disease Study 2021. Findings: In 2021, the global prevalence of anaemia across all ages was 24·3% (95% uncertainty interval [UI] 23·9–24·7), corresponding to 1·92 billion (1·89–1·95) prevalent cases, compared with a prevalence of 28·2% (27·8–28·5) and 1·50 billion (1·48–1·52) prevalent cases in 1990. Large variations were observed in anaemia burden by age, sex, and geography, with children younger than 5 years, women, and countries in sub-Saharan Africa and south Asia being particularly affected. Anaemia caused 52·0 million (35·1–75·1) YLDs in 2021, and the YLD rate due to anaemia declined with increasing Socio-demographic Index. The most common causes of anaemia YLDs in 2021 were dietary iron deficiency (cause-specific anaemia YLD rate per 100 000 population: 422·4 [95% UI 286·1–612·9]), haemoglobinopathies and haemolytic anaemias (89·0 [58·2–123·7]), and other neglected tropical diseases (36·3 [24·4–52·8]), collectively accounting for 84·7% (84·1–85·2) of anaemia YLDs. Interpretation: Anaemia remains a substantial global health challenge, with persistent disparities according to age, sex, and geography. Estimates of cause-specific anaemia burden can be used to design locally relevant health interventions aimed at improving anaemia management and prevention. Funding: Bill & Melinda Gates Foundation